Neurocrine isn't "losing" anything. It was a deliberate business decision. The math is way above your head (and mine for that matter) but bottom line, Neurocrine makes more money per rx than Teva. A lot more actually. Our baselines here are fair and straightforward. Increase your baseline by a few rx's and you'll be just fine and make plenty of money. Teva reps would kill for the sanity at this company vs the insanity at Teva.
Isn't Neurocrine paying 4-5 pharma companies not to manufacture Ingrezza? Teva is one of them. Neurocrine is paying teva a percentage for every Ingrezza sale. When you look at our 3rd qtr statement to Neurocrine is not making more money. Which is probably why we are losing coverage. Frankly, we are not at teva and could care less about how their reps are doing. It's not that great here.
Are you a manager?
Teva is a sick and pathetic companyBOOM!
TD market is largely an illusion designed to excite moronic shareholdersRelax, just relax. Neurocrine is not for sale, the time to purchase was 5+ years ago. Nothing noteworthy in the pipeline and the analysts know what the TD market will produce in the foreseeable future. Enjoy your holidays.
